Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. - sprookjes - yvandenbroek - TriplyDB

Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.

Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.

http://www.wikidata.org/entity/Q34028464

about

Role of nanotechnology and gene delivery systems in TRAIL-based therapies Avian Paramyxovirus: A Brief Review Mechanisms and applications of interleukins in cancer immunotherapy.Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice The therapeutic effect of death: Newcastle disease virus and its antitumor potential.Bispecific antibody suppresses osteosarcoma aggressiveness through regulation of NF-κB signaling pathway.Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer.Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.Molecular characterization of an apoptotic strain of Newcastle disease virus isolated from an outbreak in India.Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer Bmi‑1‑targeting suppresses osteosarcoma aggressiveness through the NF‑κB signaling pathway.Prospects for combined use of oncolytic viruses and CAR T-cells.Tunicamycin inhibits colon carcinoma growth and aggressiveness via modulation of the ERK-JNK-mediated AKT/mTOR signaling pathway.Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-κB signaling pathway.Tunicamycin suppresses breast cancer cell growth and metastasis via regulation of the protein kinase B/nuclear factor-κB signaling pathway.Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms.Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway.Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.Long non-coding RNA phosphatase and tensin homolog pseudogene 1 suppresses osteosarcoma cell growth via the phosphoinositide 3-kinase/protein kinase B signaling pathway.Viroimmunotherapy for Colorectal Cancer: Clinical Studies.Tumor necrosis factor-related apoptosis-inducing ligand additive with Iodine-131 of inhibits non-small cell lung cancer cells through promoting apoptosis.Camptothecin inhibits the progression of NPC by regulating TGF-β-induced activation of the PI3K/AKT signaling pathway.Natural Diterpenoid Isoferritin A (IsoA) Inhibits Glioma Cell Growth and Metastasis via Regulating of TGFβ-Induced EMT Signal Pathway.Viral Vectors in Gene Therapy.Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2 Bone morphogenetic protein and activin membrane-bound inhibitor suppress bone cancer progression in MG63 and SAOS cells via regulation of the TGF-β-induced EMT signaling pathway

P2860

Q28076798-85588A90-42E6-412E-8EA1-1EF20F46C4C6 Q28261383-AAF1F4EE-B95C-4FC9-A3A8-61174FC9C7D7 Q34458290-F62D35BF-D712-4EE9-9EBE-0848D355C6FC Q36140704-3B2BDDA1-2269-405E-B04E-D90508DF7D7B Q36162804-176F5681-BE2D-4FB7-BB62-E309F36A44C8 Q36393363-83E61D86-580B-4AA7-843E-35FAB412E1F3 Q38556725-DDF22B57-8681-496C-A6E9-6C574772F775 Q38699757-F5DFB1BA-6F2E-4908-B0E9-803EEC79E8FB Q38741265-1380E30F-6FD9-442D-AEE1-994DD7149477 Q39358916-8B1AA7B7-7B73-4F9E-89E0-EFB3DFB4CB02 Q39523091-0367C7E5-B610-45BE-89DF-24525BC568F2 Q40511505-44B8F585-9804-4831-B66D-9AB71E720702 Q41456207-2CC8B7B4-7DEA-40CA-B786-551159C62C09 Q41505946-0E68DC20-BC3A-425C-8721-F43AD502AE93 Q41699675-135B0B4B-878B-4C15-94DF-22DA8D374102 Q41923166-FB7875EB-73E7-4367-86ED-E7A730CC13EE Q47103891-FC1663E8-124B-465B-B7F8-0CCAF91FAEC9 Q49981787-9FD3D8D9-2261-45F7-ABBC-309955B897D3 Q50308942-9B44E55E-1325-4802-8655-6292ECBAE17D Q52655182-92E042D8-8FEC-4E6D-9111-283343E2C2C8 Q52718361-BDC13504-C023-460B-B0AF-AC172500B1FC Q54219825-F2F78ECD-3A45-40BE-89C5-E6C9EAF1A0B9 Q54241184-D393D2A8-D571-4CFB-B61B-A8FB30B167FD Q54978036-81ECCCD6-697E-49A7-B97B-05CEF928ECCD Q55085114-80DEF704-AA5B-4DB1-B556-DCDC0FEF3021 Q55240083-037D0E4F-5301-4157-A487-F6A1CE8032BA Q55348670-2661F210-3143-4F0A-B966-3018C1AB6D06 Q55361238-E7386840-78B1-4C30-8697-6BC27176F848 Q55408780-5D1B6CD6-C60D-499C-9D0B-EDE634FDD3A3 Q56892727-89A554B0-7E2A-4E40-AE35-73772C09975D Q58586410-D83CBC2B-45CC-4E9D-9816-052B46AD08DE Q58798304-0FDB34A3-6790-4526-9FA4-1E8F2351BD9B

P2860

Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.

http://www.wikidata.org/entity/Q34028464

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@ast

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@en

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@nl

type

label

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@ast

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@en

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@nl

prefLabel

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@ast

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@en

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@nl

P1433

Q34028464-0C6FAA43-CBC8-4FB2-896F-1B337BB2C0B0

P1476

Q34028464-E3CFA4B8-3442-4C3B-8D06-9090733465C1

P2093

Q34028464-09783BE2-3FDF-486B-9A19-6C8807BCD7E2

Q34028464-1BF0069C-8F2D-4228-B6DD-301BF0AD282F

Q34028464-29334FC0-7E67-45DD-8498-6A65E116A4F3

Q34028464-2B8B2FFF-E4AD-41F9-B285-2161D4EDB2E4

Q34028464-576D973C-5160-41D1-A677-23F05DDBE62A

Q34028464-60C46C3E-8241-41FF-A852-762F593D162B

Q34028464-9F29C0F6-0811-4CB9-BE68-91970AFF9B68

Q34028464-A3ECD5D1-AF4E-4727-A8F1-3DDE822E4405

Q34028464-A992B2B2-CFE6-4F01-8067-973AB8BDB539

P2860

Q34028464-08C73954-0071-4847-81B4-2AA4B43EE72F

Q34028464-0D9F5C23-F9B9-4732-BE01-161D5219C123

Q34028464-1C38401B-0660-49BD-B9EE-FD6812C6E3D2

Q34028464-1FF8FAB4-F351-472A-9502-8490BA966355

Q34028464-3290B03F-C3D4-4E81-BDF4-D3CAF1BD3B4E

Q34028464-3C59F826-A932-4E0E-8CBF-4AA88A1EF796

Q34028464-3D4D78CB-7231-4657-8A33-710633850A8A

Q34028464-42E2F83D-A1B8-42C4-B705-42CC489762A3

Q34028464-49C5901F-6448-4841-953B-13FDF254ABE3

Q34028464-4B6DF80E-1AF8-479E-BBD7-E32334AA66AD

P304

Q34028464-97720FC4-8843-49AA-9767-F0A8B0007D4B

P31

Q34028464-80BDE9F7-DA8C-4AE9-B296-321D9858954D

P356

Q34028464-1848F931-98C4-463F-AF2A-50A5AA2691F6

P433

Q34028464-9904114B-5DA0-4C19-B9AA-1620A6F8A906

P478

Q34028464-D4FE8159-93A5-4EED-8373-9E1E7EA4D541

P577

Q34028464-4B06257D-F35C-4CA1-BE3D-1C72F5664F56

P5875

Q34028464-00A07C0B-FD3F-4D4E-BDA4-7A67A31EDA89

P698

Q34028464-C4F7A8BF-3B4F-4E91-8755-E3AB7AEBBA8F

P921

Q34028464-52DD183F-CC04-4498-BFAF-02BE671D5B8F

P932

Q34028464-190417DD-A903-4ED0-A9AF-EA19F572A5AE

P356

P1433

Cancer Biology and Therapy

P1476

Genetically engineered Newcast ...... ing ligand for cancer therapy.

@en

P2093

Bing Zhou

http://www.w3.org/2001/XMLSchema#string

De-Shan Li

http://www.w3.org/2001/XMLSchema#string

Fu-Liang Bai

http://www.w3.org/2001/XMLSchema#string

Gui-Ping Ren

http://www.w3.org/2001/XMLSchema#string

Hui Tian

http://www.w3.org/2001/XMLSchema#string

Hui Wang

http://www.w3.org/2001/XMLSchema#string

Qing-Zhong Yu

http://www.w3.org/2001/XMLSchema#string

Xiao-Hui Han

http://www.w3.org/2001/XMLSchema#string

Yin-Hang Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and characterization of a new member of the TNF family that induces apoptosis

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

Genetically engineered Newcastle disease virus for malignant melanoma therapy

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy

The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses

Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses

p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines

Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells

Cancer immunotherapy

P304

1226-1238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.29686

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263477805

http://www.w3.org/2001/XMLSchema#string

P698

24971746

http://www.w3.org/2001/XMLSchema#string

P921

P932

4128865

http://www.w3.org/2001/XMLSchema#string